Investing to Protect the United States against Antimicrobial Resistance
Antimicrobial resistance (AR), when germs do not respond to the drugs designed to kill them, threatens to return us to the time when simple infections were often fatal. CDC is committed to protecting people and the future of the healthcare, veterinary and agriculture industries from the threat of antimicrobial resistance.
The most recent update to the AR Investment Map showcases CDC's critical activities in the U.S. to combat antimicrobial resistance with investments in laboratory and epidemiological expertise and public health innovation. The AR Investment Map reflects extramural funding in fiscal year 2024. CDC supports most of these activities through its AR Solutions Initiative, while also leveraging investments from successful programs across the agency for maximum efficiency.
To learn more about AR, visit CDC's Antimicrobial Resistance website
Select a location to learn more about AR programs funded in that jurisdiction.
Local health department that received funding.
Select Location
Local health department that received funding.
Location of one of CDC's AR Laboratory Network regional labs.
Location of the National Tuberculosis Molecular Surveillance Center.
The AR Investment Map includes data from CDC's largest funding categories for AR. It represents fiscal year 2024 extramural funding that supports AR activities from multiple funding lines in CDC's annual appropriations. Some work received full or partial funding from one-time supplemental appropriations.